Literature DB >> 15254554

Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules.

Yoh Dobashi1, Nobuko Takei, Shioto Suzuki, Hiroko Yoneyama, Mitsuhiko Hanawa, Akishi Ooi.   

Abstract

In order to evaluate the involvement of epidermal growth factor receptor, and to analyze the correlation between gene aberration and protein expression in mesenchymal tumors, we examined protein expression by immunohistochemistry in 125 cases of bone and soft-tissue tumors. Furthermore, amplification of epidermal growth factor receptor gene was determined by fluorescence in situ hybridization. Positive immunostaining was found in 23 cases (18.4%). Among these 23 cases, one of malignant fibrous histiocytoma showed the highest degree (3+) of protein overexpression and gene amplification as clusters of hybridization signals, indicating homogeneously staining regions. The second case of malignant fibrous histiocytoma also showed a higher degree (2+) of overexpression and coamplification of the epidermal growth factor receptor gene with the centromeric regions, indicating polysomy of chromosome 7. The levels of expression observed in immunohistochemistry were confirmed by immunoblotting and found to be comparable. Moreover, although expression of phosphorylated epidermal growth factor receptor was detected in those two cases of malignant fibrous histiocytoma, constitutive activation of extracellular signal-related protein kinase 1/2 was not observed, suggesting that activation of epidermal growth factor receptor does not necessarily and constantly lead to signal transduction to the downstream molecules. In the remaining 123 cases, including 21 cases exhibiting weak (1+) immunoreactivity, no gene amplification nor polysomy was found. Collectively, expression of epidermal growth factor receptor was observed not infrequently in mesenchymal tumors, but 'overexpression' is rare and can be attributed to an increase in gene copy number, resulting from amplification or polysomy. Although cases that scored positive for protein expression and/or gene amplification could be qualified candidates for antiepidermal growth factor receptor therapies, further examination of the status of downstream molecules in the signal cascade, such as phosphorylated epidermal growth factor receptor and extracellular signal-related protein kinase 1/2, may be required as the process of therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254554     DOI: 10.1038/modpathol.3800218

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  9 in total

1.  Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.

Authors:  Xianbiao Xie; Markus P H Ghadimi; Eric D Young; Roman Belousov; Quan-Sheng Zhu; Juehui Liu; Gonzalo Lopez; Chiara Colombo; Tingsheng Peng; David Reynoso; Jason L Hornick; Alexander J Lazar; Dina Lev
Journal:  Clin Cancer Res       Date:  2011-08-05       Impact factor: 12.531

2.  An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study.

Authors:  Huiyun Wu; Nicole E Muscato; Adriana Gonzalez; Yu Shyr
Journal:  Biomark Insights       Date:  2007-12-11

3.  Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2.

Authors:  Michiyuki Hakozaki; Hiroshi Hojo; Michiko Sato; Takahiro Tajino; Hitoshi Yamada; Shinichi Kikuchi; Masafumi Abe
Journal:  Virchows Arch       Date:  2009-11-18       Impact factor: 4.064

Review 4.  Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression.

Authors:  Jian Huang; Keqiang Chen; Wanghua Gong; Ye Zhou; Yingying Le; Xiuwu Bian; Ji Ming Wang
Journal:  Cancer Lett       Date:  2008-04-22       Impact factor: 8.679

Review 5.  Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.

Authors:  Jonathan Noujaim; Khin Thway; Zia Bajwa; Ayeza Bajwa; Robert G Maki; Robin L Jones; Charles Keller
Journal:  Front Oncol       Date:  2015-08-17       Impact factor: 6.244

6.  An internal ribosome entry site in the 5' untranslated region of epidermal growth factor receptor allows hypoxic expression.

Authors:  T E Webb; A Hughes; D S Smalley; K A Spriggs
Journal:  Oncogenesis       Date:  2015-01-26       Impact factor: 7.485

7.  EGFR is involved in dermatofibrosarcoma protuberans progression to high grade sarcoma.

Authors:  Amélie Osio; Shuo Xu; Morad El Bouchtaoui; Christophe Leboeuf; Guillaume Gapihan; Christine Lemaignan; Guilhem Bousquet; Céleste Lebbé; Anne Janin; Maxime Battistella
Journal:  Oncotarget       Date:  2018-01-03

8.  Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma?

Authors:  Jun Ah Lee; Yunmi Ko; Dong Ho Kim; Jung Sub Lim; Chang-Bae Kong; Wan Hyeong Cho; Dae-Geun Jeon; Soo-Yong Lee; Jae-Soo Koh
Journal:  Cancer Res Treat       Date:  2012-09-30       Impact factor: 4.679

9.  Rho A Regulates Epidermal Growth Factor-Induced Human Osteosarcoma MG63 Cell Migration.

Authors:  Jinyang Wang; Lei Zhang; Rongmei Qu; Lin Zhang; Wenhua Huang
Journal:  Int J Mol Sci       Date:  2018-05-11       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.